Concepedia

Author

T. Lamy

Centre Hospitalier Universitaire de Rennes

Also Known As

T Lamy, T. Lamy, Th. Lamy

21

Publications

332

Citations

9

H-Index

37

Concepts

All Affiliations

Centre Hospitalier Universitaire de RennesCentre Hospitalier Universitaire d'AngersInsermInstitut Paoli-CalmettesCentre Hospitalier Universitaire de Bordeaux
TL

About

T. Lamy is an author at Centre Hospitalier Universitaire de Rennes specializing in medicine, oncology, and immunotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

246

2

Health Sciences

2

2

65

3

Cellular Therapies

1

1

23

4

Clinical Immunology

1

1

23

5

Diagnostic Sciences

1

1

41

T. Lamy

×

8

Publications

281

Citations

8

H-Index

YearCitations

Home treatment of febrile neutropenia: An empirical oral antibiotic regimen

M Gardembas-Pain, B Desablens, Luc Sensebé,

Annals of Oncology

1991

84

A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse

Sophie Park, Nicolas Chapuis, F. Saint Marcoux,

Leukemia

2013

58

First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial.

Steven Le Gouill, Nöel Milpied, T. Lamy,

Journal of Clinical Oncology

2011

41

Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III-IV patients. The GOELAMS Group, France.

C. Foussard, B Desablens, Luc Sensebé,

PubMed

1997

25

Epidemiologic analysis of glycopeptide-resistantEnterococcus strains in neutropenic patients receiving prolonged vancomycin administration

P. Plessis, T. Lamy, Pierre-Yves Donnio,

European Journal of Clinical Microbiology & Infectious Diseases

1995

24

Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).

Bertrand Coiffier, Vincent Ribrag, Jehan Dupuis,

Journal of Clinical Oncology

2011

23

POLA‐R‐CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA

Hervé Tilly, Jeff P. Sharman, Nancy L. Bartlett,

Hematological Oncology

2017

16

Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study

Laëtitia Largeaud, Pascale Cornillet‐Lefèbvre, Jean‐François Hamel,

Leukemia

2020

10

Page 1